Frequently Asked Questions
The market is segmented based on Global Non-Invasive Cancer Diagnostics Market, By Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Colorectal Cancer, Other), Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test (POCT), Hematology, Hemostasis), Test Type (Urine Test, Imaging Test, Spectroscopy), Application (Blood, Urine, Saliva), End Users (Hospital and Clinics, Diagnostic Centers, Ambulatory Care, Others) - Industry Trends and Forecast to 2030.
.
The Global Noninvasive Cancer Diagnostics Market size was valued at USD 140.00 USD Billion in 2022.
The Global Noninvasive Cancer Diagnostics Market is projected to grow at a CAGR of 7.2% during the forecast period of 2023 to 2030.
The major players operating in the market include Abbott, Thermo Fisher Scientific , Illumina , QIAGEN, F. Hoffmann-La Roche Ltd, Agilent Technologies , Quest Diagnostics ,orporated, Merck KGaA, Hologic , BD, GSK plc., Novartis AG, Bristol-Myers Squibb Company, Lilly, Pfizer , Myriad Genetics
-.
The market report covers data from the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
